LUO Fei-hong will report a single-arm, self-controlled study of recombinant human growth hormone (Jintropin® AQ) treatment in children with Prader-Willi syndrome (PWS). This study aimed to assess the efficacy of Jintropin® AQ on motor development, mental development, retarded growth, and safety profiles in children with PWS. A total of 35 PWS children in China were enrolled to receive 0.5mg/m2/d Jintropin® AQ at first 4 weeks. Then the dose increased to 1.0 mg/m2/d from week 4 to week 52. The results demonstrated that treatment with 1.0 mg/m2/d Jintropin® AQ showed great improvement in growth parameters, including normalizing Ht SDS, BW SDS, BMI SDS and bone maturity, as well as mental development. Daily Jintropin® AQ administered subcutaneously for 52 weeks showed good safety profiles.
Lobby
Video on Demand
Exhibition Halls
Poster Gallery
PROGRAMME